Nuuron–SEVERAL: investment, 202410 seed financing round €3.5m led by HTGF

	Period	2024-10-31
	Money taker	Nuuron GmbH
	Money source	SEVERAL
	Product	digital therapeutic (dTx)
	Product 2	venture capital
	Person	Petersen, Tilmann (High-Tech Gründerfonds 202404 Investment Manager before AMSilk + CytoSwitch + Nu Emotions)

High-Tech Gründerfonds Management GmbH. (10/31/24). "Press Release: Berlin-Based Neurotech Startup Nuuron Secures Investment for the Development of a Digital Drug to Treat Alzheimer’s Disease".

Activating the Memory System of the Brain with Software to Treat Alzheimer’s Disease
Nuuron is developing a fully digital Alzheimer’s therapy based on a proprietary neuromodulation technology. Nuuron’s algorithms produce ultra-high frequency, digital-photonic stimuli that activate the Memory System of Alzheimer’s patients, aiming to improve memory formation and memory recall. This digital disease-modifying therapy uses the retina as interface into the brain and employs advanced VR and AR technologies for stimulation delivery.

Oversubscribed Round and Consortium of Renowned Investors

The Berlin-based neurotech startup Nuuron has raised €3.5 million in an oversubscribed seed financing round. The round is led by High-Tech Gründerfonds (HTGF) and includes investors such as IBB Ventures, caesar., the Business Angel Club Berlin, other business angels and family offices. In addition, Nuuron entered a strategic partnership with RoX Health, a subsidiary of the pharma and diagnostics group Roche.

Clinical Trials with Charité and DZNE – Market Entry in Europe and the U.S.

Nuuron will use this funding for animal studies in collaboration with the German Center for Neurodegenerative Diseases (DZNE) and a clinical trial with Alzheimer’s patients at Charité and to advance product development. Additionally, market entry preparations start in Europe and the U.S.

Nuuron Has Hacked the Neural Code of Memory

“Our scientists have succeeded in hacking the neural code of memory, enabling us to develop a digital drug to treat Alzheimer’s Disease. We call it the Memory Pacemaker – an effective therapy, prescribed by doctors and reimbursed by health insurances.”
Dr. Markus Müschenich, Co-Founder of Nuuron

A New Therapy Option for 100+ Million Alzheimer’s Patients

Currently, over 55 million people worldwide live with Alzheimer’s Disease and other dementias, a number expected to rise to 139 million by 2050. The market for Alzheimer’s therapies was estimated at USD 5.8 billion in 2023, with a projected increase to USD 11.4 billion by 2032.

Nuuron Demonstrates the Immense Potential of Digital Drugs

“We at RoX Health have supported Nuuron from the very beginning in a strategic collaboration, as we recognized the immense potential of their technology early on. Nuuron’s innovative approach demonstrates the possibilities that digital therapeutics offer and how we can treat complex diseases even more effectively in the future.”
Dr. Robert Schnitzler, CEO, RoX Health, Berlin & Head Digital Health Innovation, Roche Pharma AG

About Nuuron

Nuuron was founded by Fabian Queisner and Dr. Markus Müschenich. The scientific work is lead by Priv.-Doz. Dr. Julian Keil. Nuuron’s dedicated team unites specialists across neuroscience, medicine, neuroinformatics, machine learning, and public health.

Press Contact:
Dr. Markus Müschenich, MPH,
Email: [email protected]
Web: www.nuuron.com

About IBB Ventures

IBB Ventures (www.ibbventures.de) has been providing venture capital to innovative Berlin-based companies since 1997 and has established itself as the market leader in early-stage financing. The funds are primarily used for development and market launch of innovative products or services as well as for business concepts from creative industries. In addition to the two VC funds for technology and creative companies with a volume of EUR 90 million, an impact VC fund with a volume of EUR 30 million has been in the investment phase since 2022. All VC funds are financed by the Investitionsbank Berlin (IBB) and the European Regional Development Fund (ERDF), managed by the State of Berlin. IBB Ventures has already invested in more than 260 creative and technology companies in Berlin; in syndicates with partners, the start-ups received approx. EUR 1.8 billion, of which IBB Ventures has invested EUR 275 million as lead, co-lead or co-investor. IBB Ventures is the parent brand for the VC activities of IBB Beteiligungsgesellschaft.

About caesar.

caesar. is a venture capital fund based in Munich, Germany. It all started in Kaiserstrasse (“Caesar Street”), when the partners decided to turn our passion for investing into a mission. This mission is to support outstanding founders in creating a better tomorrow through technology.

About Business Angel Club Berlin

With 145+ members, BACB e.V. is the largest business angel network in the capital region and one of the most active in Germany. We see ourselves as a matchmaker between early-stage start-ups and our business angels. In the past 3 years alone, our members have invested over €14 million of venture capital in more than 50 start-ups. In addition, our Angels support around 200 startup founders every year with 800+ hours of voluntary counselling on their first steps on the way to becoming a unicorn.

About RoX Health

RoX Health is an innovation studio and venture builder within the pharmaceutical and diagnostics company Roche. The company serves as a center for innovation in digital health, providing support to startups and founders developing digital health solutions that make a significant contribution to medical care and a tangible difference for patients

About HTGF – High-Tech Gründerfonds

HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of deep tech, industrial tech, climate tech, digital tech, life sciences and chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in the pre-seed and seed phase and can make significant investments in further financing rounds. Across all funds, HTGF has over EUR 2 billion under management. Since its foundation in 2005, it has financed more than 750 start-ups and successfully sold shares in over 180 companies.

Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Protection, KfW Capital and 45 companies.

Further information can be found at HTGF.de or on LinkedIn.

Media contact

High-Tech Gründerfonds Management GmbH
Tobias Jacob, Senior Marketing & Communications Manager
T.: +49 228 – 82300 – 121
[email protected]

Tilmann Petersen – Investment Manager

Record changed: 2024-11-09

Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]